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Activation of apoptosis through transcriptional in-
duction of Puma and Noxa has long been considered
to constitute the critical (if not sole) process by which
p53 suppresses tumor development, although G1/S
boundary cell-cycle arrest via induction of the CDK
inhibitor p21 has also been thought to contribute.
Recent analyses of mice bearing mutations that
impair p53-mediated induction of select target genes
have indicated that activation of apoptosis and G1/S
cell-cycle arrest may, in fact, be dispensable for p53-
mediated tumor suppression. However, the expres-
sion of Puma, Noxa, and p21 was not abrogated in
these mutants, only reduced; therefore, the possibil-
ity that the reduced levels of these critical effectors of
p53-mediated apoptosis and G1/S-cell-cycle arrest
sufficed to prevent tumorigenesis could not be
excluded. To resolve this important issue, we have
generated mice deficient for p21, Puma, and Noxa
(p21/puma/noxa/ mice). Cells from these
mice were deficient in their ability to undergo p53-
mediated apoptosis, G1/S cell-cycle arrest, and
senescence. Nonetheless, these animals remained
tumor free until at least 500 days, in contrast to
p53-deficient mice, which had all succumbed to
lymphoma or sarcoma by 250 days. Interestingly,
DNA lesions induced by g-irradiation persisted
longer in p53-deficient cells compared to wild-type
or p21/puma/noxa/ cells, and the former
failed to transcriptionally activate several p53 target
genes implicated in DNA repair. These results
demonstrate beyond a doubt that the induction of
apoptosis, cell-cycle arrest, and possibly senes-
cence is dispensable for p53-mediated suppression
of spontaneous tumor development and indicate
that coordination of genomic stability and possiblyCother processes, such as metabolic adaptation,
may instead be critical.INTRODUCTION
p53 imposes a critical barrier against the development of cancer
(Vogelstein et al., 2000; Vousden and Lane, 2007). Approxi-
mately 50% of human cancers have mutations in this tumor-
suppressor gene, and many of the remainder harbor mutations
or epigenetic changes that impair activation of p53 or some of
its effector functions. Inherited heterozygous loss-of-function
mutations in p53 cause Li-Fraumeni syndrome in which affected
individuals are highly predisposed to developing various types of
cancers (e.g., breast cancer, sarcoma, and lymphoid malig-
nancies), often at a young age. Accordingly, mice lacking p53
(Donehower et al., 1992; Jacks et al., 1994) or bearing loss-of-
function point mutations in p53 (corresponding to amino acid
residues in p53 that are altered in Li Fraumeni syndrome patients
or in sporadic human cancers; Olive et al., 2004) develop thymic
lymphoma or sarcoma with 100% incidence between 150 and
250 days of age.
The p53 protein mostly resides in the nucleus where, upon
activation, it can bind as a homotetramer to specific DNA
sequences and thereby regulate the transcription of select
target genes (Cho et al., 1994). The p53 protein can be modified
in response to diverse stress stimuli, including DNA damage,
hypoxia, and, importantly for tumor suppression, the activation
of certain oncoproteins, such as deregulated expression of
c-Myc. In healthy (unstressed) cells, p53 levels and activity are
low, largely due to Mdm2-mediated ubiquitination, which primes
p53 for proteasomal degradation (Vousden and Lane, 2007).
Cellular stressors activate p53 via posttranslational modifica-
tions, including phosphorylation and acetylation of conserved
amino acid (aa) residues, or inhibition of Mdm2, for example,
via stimulation of p14/ARF by activated oncoproteins (Riley
et al., 2008; Vousden and Lane, 2007). p53 can then tran-
scriptionally activate or repress many target genes (200) to
initiate diverse cellular responses, including G1/S boundary
cell-cycle arrest, cellular senescence, apoptotic cell death, andell Reports 3, 1339–1345, May 30, 2013 ª2013 The Authors 1339
coordination of genomic repair (Riley et al., 2008; Vousden and
Lane, 2007). Studies using gene-targeted mice demonstrated
critical roles for certain p53 target genes in p53-mediated
effector processes. For example, the cyclin-dependent kinase
inhibitor (CDKI) p21 is essential for G1/S boundary cell-cycle
arrest (Deng et al., 1995), whereas the BH3-only proteins Puma
and (to a lesser extent) Noxa are required for induction of
apoptosis (Erlacher et al., 2005; Jeffers et al., 2003; Michalak
et al., 2008; Shibue et al., 2003; Villunger et al., 2003).
It has been widely believed that p53’s primary (possibly even
sole) tumor-suppressive function is the activation of apoptosis.
Additional roles for G1/S boundary cell-cycle arrest and cellular
senescence have also been proposed (Liu et al., 2004; Riley
et al., 2008; Vousden and Lane, 2007). The overall importance
of these three cellular responses for p53-mediated tumor sup-
pression has, however, been questioned. First, it was reported
that mice deficient for endogenous (mouse) p53 but carrying
a human p53 transgene were protected from rapid tumor devel-
opment, although their cells were unable to undergo DNA-
damage-induced apoptosis, which is p53 mediated (Dudgeon
et al., 2006). Moreover, it was found that specific aa residues
within p53 that are either involved in transactivation (Brady
et al., 2011) or modified by acetylation and thereby affect p53
binding to DNA (Li et al., 2012) were differentially required for
transcriptional induction of distinct p53 target genes, and hence
the activation of certain p53 effector processes. Diverse cell
types from mice with mutations in p53’s first transactivation
domain (L25Q, W26S in TAD1) were markedly resistant to cell-
cycle arrest and apoptosis triggered by DNA damage, because
this p53 mutant was defective in the transcriptional induction
of p21, Puma, and Noxa (Brady et al., 2011). Remarkably, in
contrast to p53-deficient mice, the homozygous p5325,26mutant
animals did not show accelerated tumor formation in a mutant
Ras-driven transgenic model of non-small cell lung cancer
(NSCLC) (Brady et al., 2011). Likewise, tumorigenesis induced
by other means, such as induction of medullablastoma caused
by loss of one allele of Ptch, was considerably reduced in
homozygous p5325,26 mutants compared to p53/ mice (Jiang
et al., 2011). Since the homozygous p5325,26 mutant cells could
still undergo p53-induced senescence, the authors proposed
that this process (triggered by currently ‘‘underappreciated’’
p53 target genes) may be critical for the tumor-suppressive
action of p53. However, data from another p53 mutant mouse
strain appear to rule out a critical role for senescence in
tumor suppression as well. The p533KR mutant lacks three
conserved aa residues that are acetylated in response to
DNA damage (and certain other cytotoxic insults) and is conse-
quently not only unable to induce apoptosis and cell-cycle
arrest but also unable to trigger cellular senescence (due to a
defect in transcriptional induction of p21, Puma, and Noxa and
other classical p53 target genes) (Li et al., 2012). Nevertheless,
only a low incidence of spontaneous tumor formation with late
onset was seen in p533KR mice (Li et al., 2012). These data, in
conjunction with the finding that p533KR/3KR mutant cells could
still induce Tigar, a p53 target gene implicated in the control of
metabolism (Li et al., 2012), led the authors to the conclusion
that this effector process might be critical for p53’s tumor-
suppressive action.1340 Cell Reports 3, 1339–1345, May 30, 2013 ª2013 The AuthorsAn important caveat of both of these p53 mutants is that the
expression of the critical effectors Puma, Noxa, and p21 was
reduced, but not completely abrogated. Therefore, it remains
unclear whether apoptosis, G1/S boundary cell-cycle arrest,
and/or cellular senescence are truly dispensable for p53-
mediated tumor suppression. To answer these questions, we
have generated mice that lack all of the critical effectors of
p53-mediated apoptosis (Puma and Noxa) and G1/S cell-cycle
arrest, as well as cellular senescence (p21), and investigated
their predisposition to cancer.
RESULTS AND DISCUSSION
Although the aforementioned two studies (Brady et al., 2011;
Li et al., 2012) constitute a substantial advance in the
understanding of how p53 suppresses tumorigenesis, there
is one important caveat. Although the transcriptional induc-
tion of the p21, Puma, and Noxa genes was severely com-
promised in the cells expressing either of these two p53
mutants, their expression was not completely abrogated
(Brady et al., 2011; Li et al., 2012). It is therefore possible that
in p5325,26/25,26 and p533KR/3KR mutant mice, the residual
expression of these effectors, induced in response to oncogene
activation, was sufficient to cause growth arrest and/or
apoptosis in incipient neoplastic cells to efficiently suppress
tumorigenesis. To unambiguously resolve the important issue
of whether any expression of these proteins is required for
p53-mediated tumor suppression, we generated mice lacking
p21 (critical for p53-induced G1/S cell-cycle arrest and cellular
senescence; Deng et al., 1995; Riley et al., 2008) as well as
Puma and Noxa (essential for p53-mediated induction of
apoptosis; Jeffers et al., 2003; Shibue et al., 2003; Villunger
et al., 2003).
Cells from p21/puma/noxa/ Mice Are Resistant
to p53-Mediated Apoptosis Triggered by DNA Damage
but Susceptible to p53-Independent Apoptotic Stimuli
The BH3-only proteins Puma, and to a lesser extent Noxa, were
previously shown to be critical for apoptosis induced by p53-
dependent stress stimuli, such as DNA damage (Erlacher et al.,
2005; Jeffers et al., 2003; Michalak et al., 2008; Shibue et al.,
2003; Villunger et al., 2003). We therefore wanted to verify that
cells from p21/puma/noxa/ mice were also resistant to
p53-mediated apoptosis. Thymocytes from p21/puma/
noxa/ mice or control animals (wild-type [WT] and p53/)
were either g-irradiated or treated with etoposide (two cytotoxic
insults that kill these cells entirely via a p53-dependent pathway;
Clarke et al., 1993; Lowe et al., 1993; Strasser et al., 1994), and
their survival was then measured by flow cytometric analysis.
Thymocytes from p21/puma/noxa/mice were profoundly
resistant to DNA-damage-induced apoptosis (Figure 1A). For
example, after 24 hr of treatment with etoposide (1 mg/ml), there
was less than 30% specific survival of WT thymocytes but >75%
specific survival of the p21/puma/noxa/ thymocytes,
which was comparable to the survival of p53/ thymocytes
(Figure 1A). In contrast, p21/puma/noxa/, p53/, and
WT thymocytes displayed comparable sensitivity to deregu-
lated calcium flux (Figure 1A), a cytotoxic stimulus that is
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Figure 1. Cells from p21/puma/noxa/
Mice Are Resistant to p53-Mediated Induc-
tion of Apoptosis, G1/S Cell-Cycle Arrest,
and Senescence
(A) Thymocytes from WT, p21/puma/
noxa/, and p53/ mice were left untreated,
exposed to 1.25 Gy g-irradiation, or treated
with 1 mg/ml etoposide or 10 mg/ml ionomycin
in vitro. Cell viability was assessed after 24 hr
by Annexin-V/PI staining followed by flow cyto-
metric analysis. Data represent mean percentage
Annexin-Vneg PIneg cells relative to medium
controls.
(B) Activated (proliferating) T lymphoblasts from
WT, p21/puma/noxa/, and p53/ mice
were either left untreated or exposed to 1.25 Gy
g-irradiation and then cultured for an additional
8 hr. Distribution of cells within the different
stages of the cell cycle (G0/G1, S, G2/M) was
determined by PI staining followed by flow cyto-
metric analysis. Data represent mean percentage
of S phase cells ± SEM.
(C) Dermal fibroblasts from WT, p21/puma/
noxa/, and p53/ mice were either left
untreated or treated with 2 mg/ml etoposide
and cultured for 96 hr. Induction of cellular
senescence was determined by SA-b-galactosidase staining. Representative images of SA-b-galactosidase-stained cells. Quantitative analysis of % SA-b-
galactosidase+ cells is shown; n=5 images/mouse (103 objective) were counted. For (A)–(C), n = 3–4 mice/genotype.
Data represent mean ± SEM. *p < 0.001.independent of p53 (Strasser et al., 1994) as well as Puma and
Noxa (Villunger et al., 2003), but is instead mediated by the
BH3-only protein Bim (Bouillet et al., 1999). These data show
that cells from p21/puma/noxa/ mice are profoundly
resistant to p53-mediated apoptosis.
Cells from p21/puma/noxa/Mice Are Resistant to
p53-Mediated G1/S Cell-Cycle Arrest and Senescence
The cyclin-dependent kinase inhibitor, p21, has previously been
showntobeessential for p53-mediatedG1/Sboundarycell-cycle
arrest and cellular senescence triggered by DNA damage (Deng
et al., 1995; Riley et al., 2008). Therefore, we examined whether
cells from the p21/puma/noxa/ mice were also resistant
to p53-mediated G1/S cell-cycle arrest and senescence. First,
mitogenically activated splenic T lymphocytes were exposed to
low dose (1.25 Gy) g-irradiation, and after 8 hr their distribution
among the different stages of the cell cycle was examined by
flow cytometric analysis. A substantial reduction (drop from
35% to 20%) in cells in the S phase was seen in WT T lym-
phoblasts, but no such reduction was observed in activated,
proliferating T cells from the p21/puma/noxa/mice, which
behaved like those from the p53/ animals (Figure 1B).
Induction of cellular senescence was examined by culturing
nontransformed, primary dermal fibroblasts for 96 hr in the pres-
ence of 2 mg/ml etoposide or, as a control, in simple medium.
Cells were then stained for the senescence-associated marker,
SA-b-galactosidase. Treatment with etoposide caused a sub-
stantial (>80%) increase in SA-b-galactosidase+ cells from WT
mice (Figure 1C). In contrast, considerably fewer cells (30%)
from p21/puma/noxa/ mice displayed this marker of
senescence after such treatment (Figure 1C). It is noteworthy
that this reductionwasnot asprofoundas the reductionobservedCin etoposide treated cells from p53/ mice (only 5% SA-
b-galactosidase+ cells) (Figure 1C). These data are consistent
with the notion that transcriptional induction of the CDK inhibitor
p21 is a substantial, but not exclusive, mediator of p53-activated
cellular senescence (Riley et al., 2008; Vousden and Lane, 2007).
Collectively, these results demonstrate that cells from p21/
puma/noxa/mice are profoundly resistant to p53-mediated
cell-cycle arrest and substantially (albeit not completely) resis-
tant to p53-mediated induction of senescence.
Unlike p53/ Mice, p21/puma/noxa/ Mice Are
Not Prone to Spontaneous Tumor Development
The p53/ mice spontaneously develop tumors (mostly thymic
lymphomas and, to a lesser extent sarcomas) with high inci-
dence at a relatively young age, with nearly 100% of animals
succumbing to malignant disease before 250 days of age
(Donehower et al., 1992; Jacks et al., 1994). Since p53-mediated
induction of apoptosis, via upregulation of Puma and to a lesser
extent Noxa, and induction of G1/S cell-cycle arrest, via upregu-
lation of p21, have been hypothesized to be critical for p53-medi-
ated tumor suppression, it follows that p21/puma/noxa/
mice lacking all of these effectors should also be tumor prone.
We therefore monitored p21/puma/noxa/ mice for tumor
development (n = 28). Remarkably, none of the p21/puma/
noxa/mice developed a tumor (or any other disease) within the
500 day observation period (Figure 2). In contrast, all (n = 125)
p53/ mice had succumbed to lymphoma or more rarely,
sarcoma, within 250 days. As expected, none of the WT mice
(n = 167) developed malignant disease by 300 days of age (Fig-
ure 2). These findings prove beyond doubt that the combined
loss of p53-mediated induction (or any induction, for that matter)
of the cell-cycle inhibitor p21 plus the apoptosismediators Pumaell Reports 3, 1339–1345, May 30, 2013 ª2013 The Authors 1341
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Figure 2. p21/puma/noxa/ Mice Are Not Predisposed to
Spontaneous Development of Cancer
WT, p21/puma/noxa/, and p53/mice (all on a C57BL/6 background;
see Experimental Procedures for how they were generated) were aged and
monitored for tumor development (n = mice/genotype *p < 0.0001).and Noxa, does not predispose mice to spontaneous tumor
development. These data do not exclude that p53-mediated
apoptosis, cell-cycle arrest, and/or senescence can exert a
tumor-suppressive action in the context of certain oncogenic
driver mutations. Indeed, loss of Puma or the combined loss of
Puma and Noxa accelerated Myc-induced lymphoma develop-
ment (Garrison et al., 2008; Michalak et al., 2009). However,
lymphoma development occurred considerably more rapidly in
Em-myc;p53+/mice (note loss of only one p53 allele) compared
to Em-myc;puma/ or Em-myc;puma/noxa/mice (Michalak
et al., 2009). These studies show that, while p53-mediated
apoptosis can contribute to tumor suppression in the context
of deregulated c-Myc expression, additional p53-mediated
processes must suppress lymphomagenesis.
Resolution of DNA Damage-Associated g-H2AX Foci
and Induction of Genes Implicated in DNA Repair
Are Normal in p21/puma/noxa/ Cells
but Impaired in Those from p53/ Mice
Given that p21-induced cell-cycle arrest and Puma/Noxa-
mediated apoptosis are dispensable for p53-mediated sup-
pression of spontaneous tumor development, which p53
effector process(es) might be critical? Interestingly, we observed
that, after DNA damage (elicited by 10 Gy g-irradiation), non-
transformed dermal fibroblasts from p53/ mice appeared to
exhibit abnormally delayed resolution of g-H2AX foci (a marker
of double-strand DNA breaks and initiation of DNA repair)
compared to WT cells (Figure 3A). Quantitative analysis revealed
a trend toward persistence of increased numbers of p53-
deficient cells with high g-H2AX foci content (>40 foci/nuclei)
6 hr after g-irradiation compared to WT cells (Figure 3B; differ-
ences are likely to be statistically significant if quantification of
images from larger numbers of p53/ and control mice could
be performed). In contrast, this process occurred normally in
dermal fibroblasts from p21/puma/noxa/ mice (Figures
3A and 3B). Consistent with the notion that p53 is critical for
the coordination of the DNA damage response, studies
in zebrafish have shown that p53 is critical for the normal1342 Cell Reports 3, 1339–1345, May 30, 2013 ª2013 The Authorskinetics of DNA repair after exposure to UV (Zeng et al., 2009)
or g-irradiation (Guo et al., 2012). Moreover, consistent with
our observation that p53-deficient but not p21/puma/
noxa/ cells are impaired in their response to DNA damage,
several p53 target genes implicated in DNA repair (e.g., Ercc5,
Mgmt, and Polk) were normally induced in response to g-irradi-
ation (5 Gy) in thymocytes from p21/puma/noxa/ mice,
but were not induced in the thymocytes from p53/ animals
(Figure 3C). We therefore favor the idea that coordination of
DNA repair is a critical effector process for p53-mediated
tumor suppression (Figure 4). After all, p53 and its homologs in
lower organisms are considered the ‘‘guardians of the genome’’
(Lane, 1992). Regulation of metabolism and perhaps additional,
presently unappreciated effector processes,may also contribute
to p53-mediated tumor suppression (Figure 4). Regardless,
the hunt for the critical tumor-suppressive p53 target genes is
relaunched.
EXPERIMENTAL PROCEDURES
Mice
All experiments with mice followed the guidelines of theMelbourne Directorate
Animal Ethics Committee. Generation and genotyping of mice deficient for
p21 (Brugarolas et al., 1995), Noxa (Villunger et al., 2003), Puma (Villunger
et al., 2003), or p53 (Jacks et al., 1994) have been described. The puma/
and noxa/ mice were generated on a C57BL/6 background using C57BL/
6-derived ES cells. The p21/ and p53/ mice were generated on a mixed
C57BL/6x129SV background using 129SV-derived ES cells but had been
backcrossed with C57BL/6 mice for more than ten generations. To generate
mice deficient for p21, Puma, and Noxa, puma+/noxa/ mice were first
crossed to p21/puma+/ to produce mice heterozygous at all alleles
(p21+/puma+/noxa+/). These triple heterozygous mice were intercrossed
to produce p21/puma+/noxa/ offspring, which were then further inter-
crossed to produce the triple-knockout (p21/puma/noxa/) animals. All
mice used for cell-viability, cell-cycle, senescence, and DNA-damage repair
experiments were 6–10 weeks of age. For long-term analysis of tumor devel-
opment, cohorts of WT (C57BL/6), p21/puma/noxa/, and p53/ mice
were monitored for >300 days for signs of illness.
Cell-Viability Assays
Thymi were harvested from mice of the indicated genotypes and thymic cell
suspensions prepared. Cells were cultured in high-glucose Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (Bovogen Biologicals), 50 mM 2-mercaptoethanol, 100 mM asparagine,
100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were plated into
96-well flat-bottom plates at a starting density of 2.5 3 105 cells/ml
(200 ml/well) and treated, as described (Strasser et al., 1991), with 1 mg/ml
etoposide (InterPharma), 1.25 Gy g-irradiation, or 10 mg/ml ionomycin
(Sigma). After 24 hr, cells were harvested and stained with fluorescein-
isothiocyanate (FITC)-conjugated Annexin-V (to reveal surface exposed
phosphatidyl-serine, a marker of apoptotic cells) plus 2 mg/ml propidium
iodide (PI; Sigma). Cell viability was determined by flow cytometric analysis
on a BD-Biosciences LSRI flow cytometer with 10,000 events recorded per
sample. Data were analyzed using FlowJo (version 8.8.7) analysis software
(Treestar). Data are presented as percentage of Annexin-VnegativePInegative
(viable) cells relative to medium treated controls and calculated using
the following equation [(% viable cellstreatment/% viable cellsuntreated)*100],
n = 3 mice/genotype.
Cell-Cycle Analysis
Spleens were harvested from mice of the indicated genotypes and single-cell
suspensions were prepared. Cells were then washed and resuspended at a
final density of 3 3 106 cells/ml in high-glucose DMEM supplemented with
10% fetal bovine serum (Bovogen Biologicals), 50 mM 2-mercaptoethanol,
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Figure 3. Loss of p53 but Not Combined
Loss of p21, Puma, and Noxa Delays Reso-
lution of DNA Damage Foci and Impairs In-
duction of Genes Implicated
(A) Dermal fibroblasts from WT, p21/puma/
noxa/, or p53/mice were either left untreated
(UT) or exposed to 10 Gy g-irradiation and sub-
jected to analysis after 1, 6, and 24 hr. Cells were
analyzed by immunofluorescent staining for the
presence of g-H2AX foci (green; a marker for
detection of double-strand DNA breaks and
initiation of repair). Counterstaining with DAPI
(blue) was used to label all nuclei. (i) g-H2AX
staining alone; (ii) g-H2AX staining and DAPI
staining. Data are representative of analysis of
n = 3 mice/genotype.
(B) Quantification of g-H2AX foci in dermal fibro-
blasts from WT, p21/puma/noxa/ , or
p53/ mice that had been either left untreated
(UT) or treated with 10 Gy g-irradiation (analysis
was performed after 1, 6, and 24 hr). Data repre-
sent percentage of cells with >40 foci/nuclei.
Confocal images from UT, n = 1 mouse/genotype;
1 hr, n = 1–3 mice/genotype; 6 hr, n = 2 mice/
genotype; 24 hr, n = 1–3 mice/genotype, were
analyzed with 50–100 cells/mouse analyzed per
time point.
(C) Thymocytes from WT, p21/puma/
noxa/, or p53/mice were either left untreated
or exposed to 5 Gy g-irradiation and harvested
after 6 hr in culture. Quantitative RT-PCR analysis of mRNA levels of p53 target genes implicated in the control of DNA repair was performed; mRNA levels
were standardized to the control gene Hmbs and data are expressed relative to untreated thymocytes (cultured for 6 hr).
n = 3 mice/genotype and data represent mean ± SEM. *p < 0.05.100 mM asparagine, 100 U/ml penicillin, and 100 mg/ml streptomycin
100 IU/ml mouse interleukin-2 (IL-2) and 100 IU/ml mouse IL-7. Cells
were plated into 6-well plates (3 ml/well), coated with antibodies to mouse
CD3 and CD28, and incubated at 37C 10% CO2 for 48 hr (after 24 hr, cells
were given 2 ml of fresh medium). At 48 hr, an aliquot of cells was harvested
and stained with antibodies to CD25 (phycoerythrin conjugated) and
CD44 (FITC conjugated) to determine the purity of activated T cells
(CD25+CD44+) within the culture (routinely >85% CD25+CD44+ cells). The
remaining cells were either left untreated or treated with a single dose of
1.25 Gy g-irradiation. Cells were then plated into 96-well flat-bottom plates
at a starting density of 2.5 3 105 cells/ml (200 ml/well) and incubated at
37C 10% CO2 for 8 hr. After 8 hr, cells were harvested, fixed, permeabilized,
and stained with propidium iodide for flow cytometric cell-cycle analysis
using a BD FACScan flow cytometer with 20,000 events recorded for
each sample. Data were analyzed using FlowJo (version 8.8.7) analysis
software (Tree Star) and distribution of cells within the distinct stages of
the cell cycle determined by applying the Dean-Jett-Fox cell-cycle modeling
algorithm to the PI fluorescence intensity profile of the cells. Data are
presented as means of average percentage of cells in S phase ± SEM,
n = 4 mice/genotype.
Senescence-Associated b-Galactosidase Activity Assay
Tails were harvested from mice of the indicated genotypes and mouse dermal
fibroblasts generated. Briefly, a longitudinal incision was made down the
length of each tail and skin removed. Skin was incubated for 24 hr at 4C in
2.5 ml Hanks Balanced Salt Solution (HBSS) (with Ca2+ and Mg2+) with
2.1 U/ml Dispase II (Roche). After 24 hr, the dermis was separated from the
epidermis and then incubated in 3 ml HBSS (with Ca2+ and Mg2+) with
0.4 mg/ml Collagenase II (Sigma) at 4C, rolling for 48 hr. The dermis was
then mashed through a 100 mmmesh sieve and the resulting cell suspensions
washed in DMEM supplemented with 8% fetal bovine serum (Bovogen Biolog-
icals). Cells were resuspended at a density of 7.5 3 105 cells/ml and 1 mlCplated into 24-well flat-bottom plates. Cells were incubated overnight at
37C 10% CO2 to allow cells to adhere. Cells were then either left untreated
or were treated with 2 mg/ml etoposide (InterPharma) for 96 hr. Cells were
then fixed in 2% formaldehyde 0.2% glutaraldehyde and incubated with
X-gal (Invitrogen) at pH 6.0 for 14 hr to determine senescence associated
b-galactosidase activity, as previously described (Dimri et al., 1995). Stained
cells were imaged using an Olympus IX70 inverted bright-field and fluores-
cence microscope using the CellSens Standard (Olympus) image-capturing
software. Five representative images/genotype at 103 objective were
counted. Data are presented as the mean percentage of b-galactosidase-
positive cells as a proportion of total cells. Error bars represent SEM,
n = 3 mice/genotype.
DNA Damage Repair Analysis Using g-H2AX Staining
Mouse dermal fibroblasts were derived as described above and 1 3 104 cells
in DMEM supplemented with 8% fetal bovine serum (Bovogen Biologicals)
were plated into 8-chamber polystyrene vessel tissue culture treated glass
slides (BD Falcon) (500 ml/well). Cells were then incubated at 37C 10%
CO2 for 2 days before being used for experiments. Cells were exposed
to 10 Gy g-irradiation (or left untreated) and then incubated at 37C
10% CO2. Cells were harvested at 1, 6, and 24 hr post-g-irradiation, fixed,
and permeabilized in eBioscience Fix/Perm solution for 30 min according
to the manufacturer’s instructions. Slides were washed with an excess
of eBioscience Perm Wash solution and then stained with FITC-conjugated
antibodies to phospho-histoneH2A.X (Ser139; Millipore) in wash solution
for 30 min. Slides were then washed, incubated with DAPI for 5 min,
washed again, and coverslipped for imaging on a Zeiss LSM5 Live
microscope. Images were analyzed with Axiovision v4.8 multidimensional
acquisition (n = 3 mice/genotype). g-H2AX foci were quantified by blinded
scoring of images. Data represent percentage of cells with >40 foci/nuclei.
Confocal images from one to three mice/genotype were analyzed with
50–100 cells/mouse analyzed per time point.ell Reports 3, 1339–1345, May 30, 2013 ª2013 The Authors 1343
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Figure 4. Model for How p53 Suppresses
Tumorigenesis
p53’s transcriptional control of apoptosis (via
Puma and Noxa), cell-cycle arrest, and senes-
cence (via p21) appears largely dispensable for
p53’s ability to suppress tumorigenesis. Note that a
role for cell senescence in p53-mediated tumor
suppression cannot be fully excluded on the basis
of our results (reflected by a faint dotted line) since
induction of senescence was only impaired in cells
from the p21/puma/noxa/ mice but abro-
gated in cells from the p53/ mice (Figure 1C).
Theseprocessesdo, however, exert critical roles in
p53-mediated cellular responses to acute DNA
damage, but this acute DNA damage response is
not essential for p53-mediated suppression of
spontaneous tumor development (Christophorou
et al., 2006). Instead, p53’s underappreciated
ability to act as a ‘‘guardian of the genome,’’ facil-
itating coordination of DNA repair and/or control of
metabolism (or control of currently unknown pro-
cesses) is hypothesized to be essential for p53’s
ability to suppress development of cancer.Quantitative RT-PCR Analysis
Total RNA was isolated from thymocytes using TRIzol (Invitrogen) and reverse
transcribed using SuperScript II Reverse Transcriptase (Invitrogen) and
Oligo-d(T) primers. Quantitative RT-PCR was performed in triplicate using
Taqman Gene Expression assays (Applied Biosystems) and an ABI 7900
Real-Time PCR machine (Applied Biosystems). The mRNA expression levels
of p53 target genes of interest were standardized by the transcript levels
of the reference gene, Hmbs, based on the comparative threshold method
(DDCt). n = 3 mice/genotype.
Statistical Analysis
Prism (version 5; GraphPad Software) software was used for all statistical
analyses. Two-group comparisons were made using two-tailed t tests
assuming equal variances. Tumor free survival data were plotted using
Kaplan-Meier curves. Differences in survival time between cohorts of mice
were tested using log-rank tests. p values less than 0.05 were considered to
indicate statistical significance.
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